52
Participants
Start Date
April 3, 2014
Primary Completion Date
February 5, 2020
Study Completion Date
February 5, 2020
Alectinib
Participants will receive 600 mg PO alectinib BID for 28 consecutive days during Cycle 1 and on Days 1-21 of each cycle thereafter (21-day cycles from Cycle 2 onwards) in Stage 1 and RP2D PO BID in Stage 2.
Atezolizumab
Participants will receive 1200 mg atezolizumab IV infusion q3w on Day 8 of Cycle 1 and on Day 1 of each cycle thereafter in Stage 1 and in Stage 2.
Erlotinib
Participants will receive 150 mg erlotinib PO QD for 28 consecutive days during Cycle 1 and on Days 1-21 of each cycle thereafter in Stage 1 (21-day cycles from Cycle 2 onwards) and RP2D PO QD in Stage 2.
Memorial Sloan Kettering - Basking Ridge, New York
START Madrid. Centro Integral Oncologico Clara Campal; CIOCC, Madrid
Florida Hospital Cancer Inst, Orlando
Case Western Reserve University; Medicine-Hematology and Oncology, Cleveland
Hospital Clinico Universitario de Valencia, Valencia
Karmanos Cancer Center; Department of Oncology, Detroit
University of Chicago, Chicago
UC Irvine Medical Center, Orange
Institut Gustave Roussy, Villejuif
The Chinese University of Hong Kong, Shatin
Yale University School Of Medicine, New Haven
Massachusetts General Hospital;Hematology/ Oncology, Boston
Beth Israel Deaconess Med Ctr; Neurology/MS Center, Boston
Dana Farber Cancer Institute, Boston
Seoul National University Hospital, Seoul
Asan Medical Center, Seoul
Queen Mary University of London, London
Hoffmann-La Roche
INDUSTRY